Analysts' View: Valeant Pharma (VRX), Sarepta Therapeutics (SRPT), GoPro (GPRO), Apple (AAPL), Anglo American (NGLOY)
Deutsche Bank has resumed coverage of Valeant Pharmaceuticals International, Inc. (NYSE:VRX) with a Hold rating and a price target of $30.00 per share
Valeant Pharmaceuticals International is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Analysts at Needham reiterated a Buy rating and raised their price target on Sarepta Therapeutics, Inc. (Nasdaq:SRPT) shares from $47.00 to $81.00
Sarepta Therapeutics is focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases.
Brokerage firm Wedbush boosted its price objective on shares of GoPro, Inc. (Nasdaq:GPRO) from $14.50 to $17.50 while maintaining an Outperform rating
GoPro produces mountable and wearable cameras (capture devices) and accessories. Its products are sold globally through retailers, wholesale distributors and on its Website.
UBS reaffirmed its Buy rating on Apple Inc. (Nasdaq:AAPL) stock while increasing its price target to $127.00 from $115.00
Apple leads the world in innovation with iPhone, iPad, the Mac and Apple Watch. Apple’s three software platforms — iOS, OS X and watchOS — provide seamless experiences across all Apple devices and empower people with breakthrough services including the App Store, Apple Music, Apple Pay and iCloud
Shares of Anglo American plc (OTCMKTS:NGLOY) were upgraded from an Underperform to a Neutral rating by investment analysts at Macquarie
Anglo American focuses its business on its portfolio of diamonds, platinum group metals and copper.
Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWEWorld Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at www.crweworld.com/finance_disclaimer